Semaglutide: The specific GLP-1 RA that makes up Ozempic, Wegovy and Rybelsus
SCFAs (especially butyrate and propionate) activate FFAR2/FFAR3 receptors on L-cells, stimulating GLP-1 secretion and improving appetite control
This guide breaks down everything known about both compounds, examines the theoretical case for combining them, maps the risks you need to understand, and provides the monitoring framework that any serious researcher would require before considering this stack
Patients with pre-existing hypotension or autonomic dysfunction may be at heightened risk of symptomatic low blood pressure, especially during the titration phase
Pharmaceutical manufacturers in the country, including Novo Nordisk, have assured diabetes patients that there is no current impact of COVID-19 on their supply chain
Keep medication separated from ice packs to prevent freezing